Liver Fibrosis as a Predictive Factor of Response to Pegylated-IFN/ Ribavirin Therapy in Chronic HCV Patients

Authors

The Department of Endemic Medicine, Gastroenterology & Tropical Hepatology, Faculty of Medicine, Cairo University*, Biochemistry & Molecular Biology Department, Theodor Bilharz Research Institute** and National Hepatology & Tropical Medicine Research Institute (NHTMRI)***

Abstract

Abstract Background: The stage of fibrosis is a sensitive predictor of sustained virological response to Pegylated INF/Ribavirin in chronic hepatitis C. Aim of Study: To assess the value of liver fibrosis as a predictor of SVR. Patients and Methods: This study was a retrospective controlled study and was performed on a total number of 240 patients who were treated by PEG-IFN alpha/RBV for 48 weeks and fibrosis stage was done for the all patients. Results: SVR was significant high in patients with F0 and F1 fibrosis stage. Conclusion: The fibrosis stage was a strong pretreatment predictor of response to pegylated interferon and ribavirin therapy in egyptian patients chronically infected with HCV genotype 4.

Keywords

The Medical Journal of Cairo University
Volume 89, September
September 2021
Pages 2197-2202

Files

Share

How to cite

Statistics